Lucid Diagnostics (NASDAQ:LUCD) Cut to “Sell” at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities analysts have also issued reports about the stock. Ascendiant Capital Markets raised their target price on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $3.94.

Lucid Diagnostics Stock Down 1.4%

Shares of NASDAQ LUCD opened at $1.37 on Friday. The stock has a market cap of $188.62 million, a PE ratio of -1.32 and a beta of 1.18. Lucid Diagnostics has a 52-week low of $0.95 and a 52-week high of $1.80. The business has a 50-day moving average price of $1.28 and a 200 day moving average price of $1.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Centiva Capital LP acquired a new position in shares of Lucid Diagnostics in the third quarter valued at approximately $25,000. Sprott Inc. acquired a new stake in shares of Lucid Diagnostics during the third quarter worth $25,000. SG Americas Securities LLC purchased a new position in Lucid Diagnostics in the 3rd quarter valued at $26,000. Quadrature Capital Ltd acquired a new position in Lucid Diagnostics in the 2nd quarter valued at $29,000. Finally, Abel Hall LLC acquired a new position in Lucid Diagnostics in the 4th quarter valued at $33,000. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.